Epidemiologic and molecular prognostic review of glioblastoma
…, DD Lightner, JS Barnholtz-Sloan, JL Villano - … , biomarkers & prevention, 2014 - AACR
Glioblastoma multiforme (GBM) is the most common and aggressive primary central nervous
system malignancy with a median survival of 15 months. The average incidence rate of …
system malignancy with a median survival of 15 months. The average incidence rate of …
Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a …
…, TJ Pluard, SA Toms, V Tse, S Peak, JL Villano… - JAMA …, 2023 - jamanetwork.com
Importance Glioblastoma is the most lethal primary brain cancer. Clinical outcomes for
glioblastoma remain poor, and new treatments are needed. Objective To investigate whether …
glioblastoma remain poor, and new treatments are needed. Objective To investigate whether …
[HTML][HTML] First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
…, TJ Pluard, V Tse, RM Green, JL Villano… - Journal of translational …, 2018 - Springer
Background Standard therapy for glioblastoma includes surgery, radiotherapy, and
temozolomide. This Phase 3 trial evaluates the addition of an autologous tumor lysate-pulsed …
temozolomide. This Phase 3 trial evaluates the addition of an autologous tumor lysate-pulsed …
Improved survival time trends for glioblastoma using the SEER 17 population-based registries
M Koshy, JL Villano, TA Dolecek, A Howard… - Journal of neuro …, 2012 - Springer
The EORTC/NCIC 22981/26981 study demonstrated an improvement in median overall
survival (OS) from 12.1 to 14.6 months in patients with glioblastoma (GBM) who received …
survival (OS) from 12.1 to 14.6 months in patients with glioblastoma (GBM) who received …
Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data
…, TA Dolecek, BJ McCarthy, JL Villano - Neuro-oncology, 2012 - academic.oup.com
Few population estimates of brain metastasis in the United States are available, prompting
this study. Our objective was to estimate the expected number of metastatic brain tumors that …
this study. Our objective was to estimate the expected number of metastatic brain tumors that …
Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized …
…, Y Kew, P Roth, R Desai, JL Villano… - JAMA …, 2018 - jamanetwork.com
Importance Tumor-treating fields (TTFields) therapy improves both progression-free and
overall survival in patients with glioblastoma. There is a need to assess the influence of …
overall survival in patients with glioblastoma. There is a need to assess the influence of …
[HTML][HTML] Clinical practice experience with NovoTTF-100A™ system for glioblastoma: the Patient Registry Dataset (PRiDe)
…, DD Tran, Y Kew, R Cavaliere, JL Villano… - Seminars in …, 2014 - Elsevier
Recurrent glioblastoma multiforme (GBM) is a highly aggressive cancer with poor prognosis,
and an overall survival of 6 to 7 months with optimal therapies. The NovoTTF-100A™ …
and an overall survival of 6 to 7 months with optimal therapies. The NovoTTF-100A™ …
Epidemiology of meningiomas post‐public law 107‐206: the benign brain tumor cancer registries amendment act
…, JP Thakkar, M Liu, A Al‐Qaisi, JL Villano - Cancer, 2015 - Wiley Online Library
BACKGROUND The current analysis follows the implementation of Public Law 107‐260, the
Benign Brain Tumor Cancer Registries Amendment Act, which mandated the collection of …
Benign Brain Tumor Cancer Registries Amendment Act, which mandated the collection of …
[HTML][HTML] Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of …
…, N Butowski, D Tran, JL Villano, L DiMeglio… - Seminars in …, 2014 - Elsevier
The NovoTTF-100A System (NovoTTF™ Therapy, Novocure Inc.) is a device that delivers
alternating electric fields (TTFields) to tumor cells and interferes with mitosis. It is approved for …
alternating electric fields (TTFields) to tumor cells and interferes with mitosis. It is approved for …
Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial
…, R Rosovsky, C Rutherford, K Sanfilippo, JL Villano… - Jama, 2023 - jamanetwork.com
Importance In patients with cancer who have venous thromboembolism (VTE) events, long-term
anticoagulation with low-molecular-weight heparin (LMWH) is recommended to prevent …
anticoagulation with low-molecular-weight heparin (LMWH) is recommended to prevent …